Summary
Unable to align the provided AI claims to the FDA-approved prescribing information because the label excerpts supplied are for COLCRYS (colchicine) tablets, while the claims are about cariprazine generic pricing; the claims do not correspond to the provided label, and multiple safety/administration-related assertions (e.g., prescriptions) are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Unsupported Statements
Generic cariprazine prices can be found on price-comparison sites like GoodRx, RxSaver, and Drugs.com.
No information in the provided COLCRYS (colchicine) label excerpts addresses cariprazine, pricing, GoodRx, or other price-comparison sites.
GoodRx pulls daily prices from thousands of pharmacies.
Not supported by the provided prescribing information excerpts (COLCRYS label contains no claims about GoodRx or pricing frequency).
GoodRx lists a generic 1.5 mg bottle for about $70–$100.
Not supported by the provided prescribing information excerpts.
Drugs.com shows a similar price range for cariprazine 3 mg and 4.5 mg strengths.
Not supported by the provided prescribing information excerpts.
Dosage strength affects cost, with 1.5 mg usually cheaper than 3 mg or 4.5 mg.
Not supported by the provided prescribing information excerpts.
Insurance coverage can reduce out-of-pocket cost to a few dollars.
Not supported by the provided prescribing information excerpts.
Some chains or discount pharmacies offer lower prices.
Not supported by the provided prescribing information excerpts.
Coupon codes from GoodRx or manufacturer discount cards can drop the price further.
Not supported by the provided prescribing information excerpts.
A 30-tablet bottle of generic cariprazine (1.5 mg) usually runs $70–$110.
Not supported by the provided prescribing information excerpts.
For generic cariprazine 3 mg or 4.5 mg strengths, the price is roughly $90–$150 for a 30-tablet quantity.
Not supported by the provided prescribing information excerpts.
These price ranges reflect the median price among listed pharmacies.
Not supported by the provided prescribing information excerpts.
GoodRx offers coupon codes that can reduce the price by 20–30%.
Not supported by the provided prescribing information excerpts.
Manufacturer discount cards, when available, may waive the copay for qualifying patients.
Not supported by the provided prescribing information excerpts.
Most Medicare, Medicaid, and private plans list generic cariprazine on their formulary.
Not supported by the provided prescribing information excerpts.
If a plan requires prior authorization, a physician’s note can speed approval.
Not supported by the provided prescribing information excerpts.
Once covered, copay amounts vary by tier—often $10–$30 per month for the generic.
Not supported by the provided prescribing information excerpts.
Colcrys and generic cariprazine both contain the same active ingredient, cariprazine.
Contradicts the provided label excerpt specifying COLCRYS active ingredient as colchicine (and the label drug described is colchicine).
Colcrys and generic cariprazine have identical dosing schedules.
Not supported by the provided prescribing information excerpts, and it is inconsistent with the labeling context (COLCRYS is colchicine with indication-specific dosing not described as cariprazine).
The generic is typically 40–70% cheaper than the brand name Colcrys.
Not supported by the provided prescribing information excerpts.
Colcrys costs $250–$400 per month.
Not supported by the provided prescribing information excerpts.
The side-effect profiles are the same because the formulation is equivalent.
Not supported by the provided prescribing information excerpts and depends on drug equivalence between colchicine (COLCRYS) and cariprazine, which is not established in the provided label.
The FDA approved the generic in 2023.
Not supported by the provided prescribing information excerpts (no FDA approval timing for cariprazine/generic referenced).
Some pharmacies may not yet stock the generic, especially in rural regions.
Not supported by the provided prescribing information excerpts.
Pharmacy pricing changes weekly.
Not supported by the provided prescribing information excerpts.
Sites like GoodRx refresh their pricing data every few days.
Not supported by the provided prescribing information excerpts.
Prices can shift after new discount programs or manufacturer rebates go into effect.
Not supported by the provided prescribing information excerpts.
Verified online pharmacies such as PharmacyChecker-accredited sites or the U.S. Pharmacopeia’s "Verified" list sell generic cariprazine.
Not supported by the provided prescribing information excerpts.
When purchasing online, the pharmacy should require a valid prescription before purchasing online.
Not addressed in the provided prescribing information excerpts for COLCRYS.
Contradictions
High
AI Statement
Colcrys and generic cariprazine both contain the same active ingredient, cariprazine.
Label Reference
Provided label excerpt identifies COLCRYS as colchicine, USP (Drug/Active ingredient: colchicine).
Important Omissions
No COLCRYS-relevant dosing, indications (gout prophylaxis/treatment of acute gout flares and FMF), contraindications, warnings/precautions, adverse reactions, or administration/storage details were provided or evaluated in the claims (the claims are largely about cariprazine pricing rather than COLCRYS prescribing information).
Importance:
High
The response makes multiple safety/clinical equivalence statements (e.g., side-effect profiles are the same; identical dosing schedules) without any support from the provided COLCRYS prescribing information excerpts.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The claims incorrectly state COLCRYS and generic cariprazine share the same active ingredient and claim identical dosing schedules/side-effect profiles. Such inaccuracies can lead to unsafe clinical substitution or misunderstanding of drug properties. This is a high-risk misalignment with the provided label, which specifies COLCRYS contains colchicine.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims are about cariprazine pricing and drug equivalence, but the provided FDA label excerpts are for COLCRYS (colchicine). The response includes a direct contradiction regarding active ingredient identity and makes unsupported clinical equivalence/safety statements.
Suggested Improvement
Limit content to topics supported by the supplied COLCRYS prescribing information excerpts (indications, COLCRYS-specific dosing, contraindications, warnings/precautions, adverse reactions, and specific-population guidance). Remove any cross-drug comparisons with cariprazine unless the correct label for cariprazine is provided.